Povetacicept reduced proteinuria by 52% vs 4.3% with placebo at week 36 in adults with IgA nephropathy in the phase 3 RAINIER trial’s interim analysis.
|Articles|June 13, 2012
Healthcare Law or Not, Insurance Is Set to Change
Advertisement
As the Supreme Court prepares to rule on the federal health overhaul, health insurers are in the spotlight. The law has been reshaping the health insurers' business—requiring, for instance, that they spend a set share of premium dollars on health care, or send refunds to customers if they fall short—and this month could see the law vanish or change markedly.
Read the full story:
Source: The Wall Street Journal
Advertisement
Related to this article
At ASN Kidney Week 2026, nephrologists said value-based kidney models improved dialysis starts, but payment cuts and MA growth are pushing practices out.
Speakers at ASN Kidney Week urge nephrologists to appeal prior authorization denials, include children in trials, and expand access to glomerular disease therapies globally.
Jennifer Flythe, MD, MPH, discusses individualizing dialysis volume management and why guideline-directed therapy use lags in advanced CKD.
Outpatient dialysis for unfunded patients with ESKD cut ED reliance and costs, while church-based CKD screening improved blood pressure.
Asian expert consensus updates mantle cell lymphoma treatment guidelines, highlighting uneven BTK inhibitor, ibrutinib and CAR T-cell access across Asia.
At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.
At IDWeek 2026, Atul Gawande, MD, MPH, said USAID cuts are costing lives but that the field is "not back at square one."
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Former USAID Health Chief Says Aid Cuts Are Costing Children's Lives
3
How ID, HIV Clinicians Can Influence Policy in an Election Year
4
It’s the Best of Times and Worst of Times for Cancer Care in Tampa
5